Clinical trial

#Chronic kidney disease (CKD) #Clinical trial #Japan

Asahi Kasei Pharma advances refractory disease drug to trial 

Asahi Kasei Pharma has advanced its treatment for refractory diseases to Phase I clinical trial.  AK1960, a novel Endothelin A (ETA) receptor antagonist, has been developed in collaboration with drug discovery company Alchemedicine, which entered a license agreement with Asahi Kasei Pharma in 2022.  In preclinical… Read More

#News

Ovarian cancer cells
#Clinical trial #Oncology #Ovarian cancer

Ovarian cancer treatment could prevent peritoneal recurrence 

A new treatment for ovarian cancer could prevent peritoneal recurrence, data suggests.  Biotech company Oncoinvent is set to present results from the Phase I study of Radspherin after cytoreductive surgery in patients with platinums ensitivesensitive epithelial ovarian cancer. According to data released in advance, nine of 10 patients treated on the highest dose remained free… Read More

#Cancer Research #News

Node structures in the central nervous system
#Clinical trial #Newron Pharmaceuticals #Schizophrenia

Newron raises €38m to advance schizophrenia treatment 

Biopharmaceuticals company Newron Pharmaceuticals has secured €38 million to advance novel therapies for patients with diseases of the central and peripheral nervous system.  The capital, raised through newly issued shares, is set to accelerate the company’s ENIGMA-TRS Phase III programme, evaluating the safety and efficacy of evenamide as an add-on therapy… Read More

#News

Blood tests in laboratory
#Clinical trial #Crohn's disease #Ulcerative colitis (UC)

Infliximab could restore disease response after drug holiday 

Subcutaneous (SC) infliximab could restore and maintain disease response in most Crohn’s disease (CD) and ulcerative colitis (UC) patients, data shows.  Results announced by biopharmaceutical company Celltrion demonstrated that initiating subcutaneous (SC) infliximab after a treatment interruption, following intravenous (IV) infliximab induction, helps patients with Crohn’s disease (CD) and ulcerative colitis… Read More

#News

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK

DDW Highlights: 17 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers made a key discovery into cancer survival. Elsewhere, a global research effort… Read More

#Podcasts

Respiratory system
#Cereno Scientific #Clinical trial #Hypertension #Idiopathic pulmonary fibrosis

Cereno Scientific to evaluate IPF drug as PH-ILD treatment 

An innovative drug developed to treat idiopathic pulmonary fibrosis (IPF) will now be evaluated as a treatment for pulmonary hypertension associated with interstitial lung disease (PH-ILD).  CS014, a HDAC inhibitor developed by biotech company Cereno Scientific, will be studied as a treatment for PH-ILD to address a… Read More

#News

#Advanced Therapies #Cell therapy #Clinical trial #Rare diseases

BOOST appoints Schambye as CEO, advances cell therapy treatment  

Biopharmaceutical company BOOST Pharma has appointed Hans Schambye as Chief Executive Officer.   BOOST, a company developing novel, first–in–class off-the-shelf cell therapies for rare, debilitating paediatric skeletal diseases, announced Schambye has transitioned from his role on the Board of Directors with immediate effect into his new role as… Read More

#News

#ABPI #Biomanufacturing #Cancer research #Clinical trial #Diabetes #European Union #FDA #Fujifilm #Oncology #Priority Review #Rare diseases #RNA #UK #United States

This week in Drug Discovery (9 – 13 February) 

News round-up for 9 – 13 February by Bruno Quinney, Content Team at DDW.  This week in DDW, researchers have made a key discovery into cancer survival. Elsewhere, a global research effort into kidney disease is underway.  The top stories:    Researchers identify RNA linked to cancer… Read More

#News

Human liver
#Clinical trial #Colorectal cancer #Liver disease

HepaRegeniX completes Phase Ib trial for liver regeneration drug 

Biotech company HepaRegeniX has completed a Phase Ib study evaluating a treatment for liver regeneration in patients undergoing minor liver resection.  Five patients in the clinical trial were treated with HRX-215 for a period of 28 days after a minor liver resection due to liver metastases originating from colorectal cancer. … Read More

#News

Researcher pipetting samples in microplate
#ABPI #Clinical trial #Non-animal model (NAM) #UK

UK must develop better pre-clinical models, ABPI warns 

The Association of the British Pharmaceutical Industry (ABPI) has urged scientists to develop better pre-clinical models to accelerate the development of new medicines. The ABPI, in collaboration with the National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs), has published a landmark review examining the UK's capabilities… Read More

#News #Regulatory

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK government #University of Sydney

DDW Highlights: 10 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative therapies showed the way to more effective cancer treatments. Elsewhere, how can… Read More

#Podcasts

Non-small cell lung cancer
#Biomica #Clinical trial #Kidney cancer #Lung cancer

Collaboration to advance drug enhancing immunotherapy response 

Biotech company Shanghai Lishan has entered a licensing agreement with computational chemistry company Evogene for a treatment enhancing immunotherapy response.  BMC128, a potential first-in-class, microbiome-based therapeutic, is designed to enhance anti-tumour activity. The treatment, developed by Evogene’s subsidiary Biomica, is a live biopharmaceutical consortium composed of four human gut bacterial strains with… Read More

#Business & Investment #News

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK #UK government #University of Sydney

This week in Drug Discovery (2 – 6 February) 

News round-up for 2 – 6 February by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies could pave the way to more effective cancer treatments. Elsewhere, how can brain function be improved in Alzheimer’s patients?  The top stories:      Immunotherapy before surgery… Read More

#News

CT scans of the brain
#Alzheimer's #Biopharma #Clinical trial #Fast Track designation #FDA

Therapy could improve brain function in Alzheimer’s patients

An investigational therapy could improve cognition, function and brain atrophy measures in Alzheimer’s patients, data shows.  Valiltramiprosate, which received Fast Track designation from the US Food and Drug Administration (FDA) in 2017, is an investigational oral agent being evaluated as a potential first-in-class, disease-modifying treatment for Alzheimer’s disease… Read More

#News

#AI #Biotech #Breast cancer #Clinical trial #Obesity

Why AI, obesity and breast cancer will dominate 2026

The latest episode of the DDW podcast is available to listen to below. This week, Bruno Quinney speaks to DDW Editor Reece Armstrong and Deputy Editor Diana Turner to look ahead to the world of drug discovery, pharma and biotech in 2026. They explore why AI will continue to dominate… Read More

#Featured Podcasts #Podcasts

Researcher in lab
#Clinical trial #CRO

CRO Pharmagene announces re-launch and lab acquisition 

CRO Pharmagene Discovery Services has announced its re-launch, coinciding with its purchase of a human tissue laboratory business.  Pharmagene, originally founded in 1996, has acquired a business near Cambridge, UK. The company says the business is specialised in the performance of laboratory-based research services using consented human tissue across both preclinical and… Read More

#News